Stifel Sees 60% Downside to ProQR (PRQR) on Ph.2/3 ILLUMINATE Data, Model Under Review
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating on ProQR Therapeutics N.V. (NASDAQ: PRQR) following recently reported Ph.2/3 ILLUMINATE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
